I Vynnychenko
I Vynnychenko
Підтверджена електронна адреса в med.sumdu.edu.ua
НазваПосиланняРік
Platinum-based chemotherapy plus cetuximab in head and neck cancer
JB Vermorken, R Mesia, F Rivera, E Remenar, A Kawecki, S Rottey, ...
New England Journal of Medicine 359 (11), 1116-1127, 2008
24002008
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
R Pirker, JR Pereira, A Szczesna, J Von Pawel, M Krzakowski, R Ramlau, ...
The Lancet 373 (9674), 1525-1531, 2009
16002009
Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial
JA Ajani, W Rodriguez, G Bodoky, V Moiseyenko, M Lichinitser, ...
J Clin Oncol 28 (9), 1547-1553, 2010
5502010
Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung …
MA Socinski, I Bondarenko, NA Karaseva, AM Makhson, I Vynnychenko, ...
J Clin Oncol 30 (17), 2055-2062, 2012
4912012
International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung …
GV Scagliotti, I Vynnychenko, K Park, Y Ichinose, K Kubota, F Blackhall, ...
1772012
First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data …
U Gatzemeier, J Von Pawel, I Vynnychenko, P Zatloukal, F de Marinis, ...
The lancet oncology 12 (1), 30-37, 2011
1232011
RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab In Combination with Chemotherapy for Second-Line …
A Brufsky, I Bondarenko, V Smirnov, S Hurvitz, E Perez, O Ponomarova, ...
Cancer Research 69 (24 Supplement), 42-42, 2009
1072009
IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab+ carboplatin+ paclitaxel or nab-paclitaxel vs carboplatin+ nab-paclitaxel as 1L …
RM Jotte, F Cappuzzo, I Vynnychenko, D Stroyakovskiy, DR Abreu, ...
J Clin Oncol 36 (18 suppl), LBA9000, 2018
1042018
Multicenter phase III comparison of cisplatin/S-1 (CS) with cisplatin/5-FU (CF) as first-line therapy in patients with advanced gastric cancer (FLAGS): secondary and subset …
JA Ajani, W Rodriquez, G Bodoky, V Moiseyenko, M Lichinitser, ...
Journal of Clinical Oncology 27 (15S), 4511-4511, 2009
792009
Effect of a proposed trastuzumab biosimilar compared with trastuzumab on overall response rate in patients with ERBB2 (HER2)–positive metastatic breast cancer: a randomized …
HS Rugo, A Barve, CF Waller, M Hernandez-Bronchud, J Herson, J Yuan, ...
Jama 317 (1), 37-47, 2017
622017
Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma
BI Rini, ER Plimack, V Stus, R Gafanov, R Hawkins, D Nosov, F Pouliot, ...
New England Journal of Medicine 380 (12), 1116-1127, 2019
482019
Prognostic factors in patients with advanced non-small cell lung cancer: data from the phase III FLEX study
R Pirker, JR Pereira, A Szczesna, J Von Pawel, M Krzakowski, R Ramlau, ...
Lung Cancer 77 (2), 376-382, 2012
472012
FAST: An international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without IMAB362, a first-in-class anti-CLDN18. 2 …
SE Al-Batran, MH Schuler, Z Zvirbule, G Manikhas, F Lordick, A Rusyn, ...
Journal of Clinical Oncology 34 (18_suppl), LBA4001-LBA4001, 2016
352016
An international, randomized, placebo-controlled, double-blind phase III study (MONET1) of motesanib plus carboplatin/paclitaxel (C/P) in patients with advanced nonsquamous non …
G Scagliotti, I Vynnychenko, Y Ichinose, K Park, K Kubota, FH Blackhall, ...
Journal of Clinical Oncology 29 (18_suppl), LBA7512-LBA7512, 2011
302011
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label …
TSK Mok, YL Wu, I Kudaba, DM Kowalski, BC Cho, HZ Turna, G Castro Jr, ...
The Lancet 393 (10183), 1819-1830, 2019
232019
Results of a randomized, phase III trial of nab-paclitaxel (nab-P) and carboplatin (C) compared with cremophor-based paclitaxel (P) and carboplatin as first-line therapy in …
MA Socinski, IN Bondarenko, NA Karaseva, A Makhson, I Vynnichenko, ...
Journal of Clinical Oncology 28 (18_suppl), LBA7511-LBA7511, 2010
232010
Heritage: A phase III safety and efficacy trial of the proposed trastuzumab biosimilar Myl-1401O versus Herceptin.
HS Rugo, A Barve, CF Waller, M Hernandez-Bronchud, J Herson, J Yuan, ...
Journal of Clinical Oncology 34 (18_suppl), LBA503-LBA503, 2016
162016
Clinical benefit and health-related quality of life assessment in patients treated with cisplatin/S-1 versus cisplatin/5-FU: secondary end point results from the first-line …
G Bodoky, ME Scheulen, F Rivera, J Jassem, A Carrato, V Moiseyenko, ...
Journal of gastrointestinal cancer 46 (2), 109-117, 2015
132015
An Open-Label, Multicenter, Randomized Phase Ib/II Study of Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second-Line Therapy in …
CF Waller, I Vynnychenko, I Bondarenko, Y Shparyk, JP Hodge, ...
Clinical lung cancer 16 (2), 92-99, 2015
132015
Motesanib plus carboplatin/paclitaxel in patients with advanced squamous non–small-cell lung cancer: Results from the randomized controlled MONET1 study
S Novello, GV Scagliotti, O Sydorenko, I Vynnychenko, C Volovat, ...
Journal of Thoracic Oncology 9 (8), 1154-1161, 2014
132014
У даний момент система не може виконати операцію. Спробуйте пізніше.
Статті 1–20